免疫检查点抑制剂相关性肠炎的回顾性分析

打开文本图片集

【中图分类号】R979.1 【文献标识码】A

【Abstract】 Objective To analyze the characteristics of immune checkpoint inhibitor （ICI）-induced colitis and to evaluate the treatment outcomes in patients.Methods This singlecenter retrospective study collected confirmed cases of ICI-induced colitis from the Sixth Affiliated Hospital of Sun Yat-sen University between January 2021 and December 2024. Data on patients baseline characteristics，medication regimens，clinical manifestations，endoscopic and pathological features， and treatmentoutcomes were analyzed.Results A totalof20 ICI-related colitis cases were included.Patient agesranged from 33 to 88years，with 16 cases （80.0%） beingmale. Themedian time to onsetof ICI-induced colitis was 77 days，with PD-1 inhibitors accounting for the highest proportion （17 cases， 85.0% ）.Patients predominantly presented with diarrhea，accompanied by abdominal pain and hematochezia.Endoscopic findings showed pancolonic involvement， with histopathology demonstrating inflammatory cellinfiltrationand crypt distortion.The treatment strategy was based on glucocorticoids or mesalazine， with favorable outcomes observed in refractory cases following the addition of biologic agents. Conclusion ICI-induced colitis presents distinct clinicopathological features.Hierarchical treatment strategy demonstrates favorable outcomes.Baseline characteristics and endoscopic findings of patients hold significant value for prognostic assessment.

【Keywords】Immune checkpoint inhibitors; Drug-induced colitis; Immunotherapy toxicity; Risl factors; Retrospective analysis

免疫检查点抑制剂（immunecheckpointinhibitors，ICI）是近年来肿瘤治疗领域的重大突破，主要包括靶向程序性死亡受体1（programmeddeath-1，PD-1）抑制剂、程序性死亡受体配体1（programmeddeathligand-1，PD-L1）抑制剂以及细胞毒性T淋巴细胞相关抗原4（cytotoxic Tlymphocyte-associatedantigen-4，CTLA-4）抑制剂。（剩余14713字）